Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: The MRC COIN trial
Madi A., Fisher D., Wilson RH., Adams RA., Meade AM., Kenny SL., Nichols LL., Seymour MT., Wasan H., Kaplan R., Maughan TS.
Background: COIN compared first-line continuous chemotherapy with the same chemotherapy given intermittently or with cetuximab in advanced colorectal cancer (aCRC). Methods: Choice between oxaliplatin/capecitabine (OxCap) and oxaliplatin/leucovorin (LV)/infusional 5-FU (OxFU) was by physician and patient choice and switching regimen was allowed. We compared OxCap with OxFU and OxCapcetuximab with OxFUcetuximab retrospectively in patients and examined efficacy, toxicity profiles and the effect of mild renal impairment. Results: In total, 64% of 2397 patients received OxCap(cetuximab). Overall survival, progression free survival and overall response rate were similar between OxCap and OxFU but rate of radical surgeries was higher for OxFU. Progression free survival was longer for OxFU±cetuximab compared with OxCapcetuximab but other efficacy measures were similar. Oxaliplatin/LV/infusional 5-FU (cetuximab) was associated with more mucositis and infection whereas OxCap(cetuximab) caused more gastrointestinal toxicities and palm ar-plantar erythema. In total, 118 patients switched regimen, mainly due to toxicity; only 16% came off their second regimen due to intolerance. Patients with creatinine clearance (CrCl) 50-80 ml min 1 on OxCap(cetuximab) or OxFUcetuximab had more dose modifications than those with better renal function.Conclusions:Overall, OxFU and OxCap are equally effective in treating aCRC. However, the toxicity profiles differ and switching from one regimen to the other for poor tolerance is a reasonable option. Patients with CrCl 50-80 ml min 1 on both regimens require close toxicity monitoring. © 2012 Cancer Research UK All rights reserved.